CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Inclusion Criteria

• •Histologically or cytologically confirmed diagnosis of clear cell renal cell carcinoma
• •Progressed on at least one standard therapy with VEGFR TKI
• •Measurable disease per Recist v1.1
• •Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1
• •Life expectancy of at least 12 weeks
• •Adequate organ functions, and meet the following requirements:
• •Bone marrow: ANC ≥1.5\*109/L (1500/mm3), platelet ≥100\*109/L, and hemoglobin ≥9 g/dL Liver: Total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤5x the upper limit of normal with liver involvement Kidney: Creatinine ≤ 1.25 x ULN, urine protein \<1+ Heart: LVEF ≥ 50%
• •Willingness and ability to comply with trial and follow-up procedures
• •Ability to understand the nature of this trial and give written informed consent